{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055647","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.174997+00:00","generated_at":"2026-06-02T08:35:36.102011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago","bullets":["NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)","Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023","Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M","Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023","Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055647","json":"https://secwatch.observer/filing/0000950170-24-055647.json","markdown":"https://secwatch.observer/filing/0000950170-24-055647.md","text":"https://secwatch.observer/filing/0000950170-24-055647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/0000950170-24-055647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/acad-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:35:36.102011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d40e8006ccd4beb4748964e7b5ed137fe009ffaa","claim":"ACADIA PHARMACEUTICALS INC reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/0000950170-24-055647-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}